Patent ID: 9588120
Date: 2017-03-07
CPC Classifications: C12Q,G01N

Claim:
1. A method of determining the aggressiveness of a ductal carcinoma in situ (DCIS) lesion of the breast, the method comprising: (a) detecting the level of GRAP2 protein in a sample from the DCIS lesion by immunohistochemistry, Western blot, or enzyme-linked immunosorbent assay (ELISA); (b) comparing the level of GRAP2 protein in the sample against a normal level of GRAP2 protein; (c) detecting the DNA copy number of CELSR1 in the sample by array comparative genomic hybridization (aCGH), quantitative polymerase chain reaction (qPCR), or in situ hybridization; (d) comparing the DNA copy number of CELSR1 in the sample against a normal DNA copy number of CELSR1, wherein the normal DNA copy number of CELSR1 is two; and (e) determining the aggressiveness of the DCIS lesion based on the comparison in steps (b) and (d), wherein an increased level of GRAP2 protein and a decreased DNA copy number of CELSR1 in the sample as compared to the normal level of GRAP2 protein and CELSR1 DNA copy number indicates an aggressive DCIS lesion.